### Supporting Information

## Enantioselective C–H Amidation of Sulfondiimines for the Synthesis of 1,2,4-Benzothiadiazine-1-Imines under Cobalt Catalysis

Ayami Murata,<sup>1</sup> Tomonori Endo,<sup>2</sup> Yuki Hirata,<sup>1</sup> Kosuke Higashida,<sup>2</sup> Tatsuhiko Yoshino,<sup>2\*</sup> Shigeki Matsunaga.<sup>1,2\*</sup>

<sup>1</sup>Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-ku, Sapporo, Japan.
<sup>2</sup>Department of Chemistry, Graduate School of Science, Kyoto University, Sakyo-ku, Kyoto, Japan.
Email: <u>yoshino.tatsuhiko.5j@kyoto-u.ac.jp</u>

matsunaga.shigeki.5x@kyoto-u.ac.jp

### **Table of Contents**

1. General	S2
2. Experimental procedures	S3
2-1. Preparation of substrates	S3
2-2. Cobalt(III)/chiral carboxylic acid-catalyzed enantioselective C(sp <sup>2</sup> )-H amidation of sulfondiimines .	S4
2-3. Determination of the absolute configuration of 3aa	S25
3. DFT calculations and non-covalent interaction plots.	S27
4. Reference	S31
5. NMR Spectra	S32


#### 1. General

All non-aqueous reactions were carried out in a flame-dried glassware under argon atmosphere unless otherwise noted or in an argon-filled glovebox. NMR spectra were recorded on JEOL JNM-ECA600 spectrometers operating at 600.17 MHz for <sup>1</sup>H NMR, 150.92 MHz for <sup>13</sup>C NMR, and 564.69 Hz for <sup>19</sup>F NMR, JEOL JNM-ECA 600 spectrometers operating at 594.17 MHz for <sup>1</sup>H NMR, 149.41 MHz for <sup>13</sup>C NMR, JEOL JNM-ECZ 600 spectrometers operating at 599.67 MHz for <sup>1</sup>H NMR. Chemical shifts were reported in the scale relative to TMS (0.00 ppm for <sup>1</sup>H NMR in CDCl<sub>3</sub>), CHCl<sub>3</sub> (7.26 ppm for <sup>1</sup>H NMR in CDCl<sub>3</sub>), CDCl<sub>3</sub> (77.00 ppm for <sup>13</sup>C NMR in CDCl<sub>3</sub>) and PhCF<sub>3</sub> (–63.72 ppm for <sup>19</sup>F NMR) as an internal reference, respectively. Column chromatography was performed with Kanto Silica gel 60 N (40-50 mesh) or Yamazen YFLC AI-580 using Universal Column SiOH. High resolution mass spectrometry (HRMS) was performed on a Bruker micrOTOF II-KR spectrometer in Atmospheric Pressure Chemical Ionization (APCI) method using "LC/MS tuning mix, for APCI, low concentration" as the internal standard. Optical rotations were measured on a JASCO P-1030 digital polarimeter at the sodium D line (589 nm). Analytical high performance liquid chromatography (HPLC) was performed on a JASCO PU-1580 intelligent HPLC pump with JASCO MD-4017 PDA detector using Daicel Chiralpak columns (0.46 cm × 25 cm). Retention times (tR) and peak ratios were determined with JASCO-ChromNAV analysis system.


Materials: Dichloromethane (DCM) and toluene were purified by Glass Contour solvent purification system before use. *t*AmOH was purchased from Aldrich (anhydrous grade) and used as received. Sulfondiimines 1,<sup>[S1]</sup> dioxazolones 2,<sup>[S2]</sup> chiral carboxylic acids (A1–A5),<sup>[S3]</sup> and Cp\*Co(CO)I<sub>2</sub><sup>[S4]</sup> were synthesized according to the previously described methods. All other reagents were commercially available and used as received unless otherwise noted.

# Experimental procedures Preparation of substrates

### Preparation of sulfondiimine 1d



To a solution of ethyl *O*-(mesitylenesulfonyl)acetohydroxamate (1.7 g, 6.0 mmol, 1 equiv.) in 1,4-dioxane (6 mL) was added 60% perchloric acid (3.9 mL) dropwise at 0 °C. After additional vigorous stirring for 10 min at 0 °C, cold water was added and the product was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum to approximately 1 mL. This mixture was slowly added to a solution of bis(4-(trifluoromethyl)phenyl)sulfane (1.1 g, 6.0 mmol, 1 equiv.) in CH<sub>2</sub>Cl<sub>2</sub> (6 mL) at 0 °C. The reaction mixture was stirred at room temperature for 12 h. Approximately half of the CH<sub>2</sub>Cl<sub>2</sub> was evaporated, and diethyl ether (12 mL) was added. The product crystallized upon storage at -30 °C overnight and was collected by filtration and dried in high vacuum to give the corresponding sulfiliminium salt **S1** (1.7 g, 3.6 mmol, 60%). <sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 600.17 MHz)  $\delta$  8.13 (s, 2H), 7.97 (d, *J* = 8.2 Hz, 4H), 7.62 (d, *J* = 8.2 Hz, 4H), 6.79 (s, 2H), 2.45 (s, 6H), 2.24 (s, 3H). <sup>13</sup>C{<sup>1</sup>**H**} **NMR** (CDCl<sub>3</sub>, 150.92 MHz)  $\delta$  139.3, 139.1, 136.9, 136.7, 135.2 (q, <sup>2</sup>*J*<sub>C-F</sub> = 33.7 Hz), 130.8, 129.2, 127.4 (q, <sup>3</sup>*J*<sub>C-F</sub> = 3.4 Hz), 122.7 (q, <sup>1</sup>*J*<sub>C-F</sub> = 275.0 Hz), 22.8, 20.6. <sup>19</sup>**F NMR** (CDCl<sub>3</sub>, 564.67MHz)  $\delta$  - 63.6. **HRMS** (ESI) m/z: [M-MesSO<sup>-</sup>]<sup>+</sup> Calcd for C<sub>14</sub>H<sub>10</sub>F<sub>6</sub>NS<sup>+</sup>: 388.0433; Found 388.0433.



To a solution of the obtained sulfiliminium salt **S1**(1.6 g, 3.0 mmol, 1.0 equiv.) and Na<sub>2</sub>CO<sub>3</sub> (5.0 equiv.) in MeCN (12 mL) was added Selectfluor® (1.0 equiv.) at 0 °C and the mixture was stirred for 12 h at room temperature. The mixture was quenched by water and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. To the residue was added to a solution of PhNH<sub>2</sub> (0.81 mL, 9.0 mmol, 3.0 equiv.) and pyridine (0.29 mL, 3.6 mmol, 1.2 equiv.) and the mixture was stirred for 24 h at room temperature. The residue was purified by silica gel column chromatography (hexane/AcOEt) and evaporated under vacuum. The residual solid was washed by hexane and filtered to give sulfondiimine **1e** (0.19 g, 0.44 mmol, 15%). **<sup>1</sup>H NMR** (CDCl<sub>3</sub>, 600.17 MHz)  $\delta$  8.32 (d, *J* = 8.2 Hz, 4H), 7.74 (d, *J* = 8.2 Hz, 4H), 7.20-7.11 (m, 4H), 6.94-6.89 (m, 1H). <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 150.92 MHz)  $\delta$  146.2, 144.5, 134.1 (q, <sup>2</sup>*J*<sub>C-F</sub> = 33.2 Hz), 129.1, 128.7, 126.4 (q, <sup>3</sup>*J*<sub>C-F</sub> = 3.4 Hz), 123.3, 123.2 (q, <sup>1</sup>*J*<sub>C-F</sub> = 273.1 Hz), 121.7. <sup>19</sup>F NMR (CDCl<sub>3</sub>, 564.67MHz)  $\delta$  -63.2. HRMS (ESI) m/z: [M+H]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>15</sub>F<sub>6</sub>N<sub>2</sub>S<sup>+</sup>: 429.0855; Found 429.0857. **Rf** 0.1 (hexane/DCM = 1:3).


All other sulfondiimines were reported in our previous work.[S1]

### 2-2. Cobalt(III)/chiral carboxylic acid-catalyzed enantioselective C(sp<sup>2</sup>)-H amidation of sulfondiimines

#### **General Procedure**


In an argon-filled glovebox, a screw-cap test tube was charged with Cp\*Co(CO)I<sub>2</sub> (9.5 mg, 0.020 mmol, 10 mol %), AgOTf (10.3 mg, 0.040 mmol, 20 mol %), chiral acid A5 (8.8 mg, 0.020 mmol, 10 mol %), sulfondiimine 1 (0.24 mmol, 1.2 equiv.), dioxazolone 2 (0.20 mmol, 1.0 equiv.), and *t*AmOH (400  $\mu$ L). The test tube was capped, and then brought out of the glovebox. The reaction mixture was stirred for 24 h at 80 °C. The reaction mixture was filtered through a short pad of silica gel, eluted with AcOEt, and evaporated under reduced pressure. The crude product was purified by silica gel column chromatography (DCM/hexane) to afford **3**.

#### (S)-3-(4-fluorophenyl)-N,1-diphenyl-116-benzo[e][1,2,4]thiadiazin-1-imine (3aa)




General Procedure 3aa using compound 1a (70.2 mg, 0.24 mmol) and 2a (36.2 mg, 0.2 mmol) and purification by silica gel column chromatography (DCM/hexane = 2/1) afforded 3aa as a colorless solid (62.6 mg, 76%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600.17 MHz) δ 8.46-8.41 (m, 2H), 8.17-8.13 (m, 2H), 7.65-7.57 (m, 3H), 7.56-7.50 (m, 2H), 7.47 (d, *J* = 7.9 Hz, 1H), 7.19-7.15 (m, 1H), 7.15-7.10 (m, 2H), 7.09-7.05 (m, 2H), 6.90-6.83 (m, 3H).

<sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 150.92 MHz) δ 164.8 (d, <sup>1</sup>*J*<sub>C-F</sub> = 250.0 Hz), 159.0, 149.9, 143.2, 141.6, 134.2, 134.1 (d, <sup>4</sup>*J*<sub>C-F</sub> = 2.9 Hz), 133.2, 130.6 (d, <sup>3</sup>*J*<sub>C-F</sub> = 8.7 Hz), 129.2, 129.1, 128.5, 128.2, 126.1, 125.3, 123.6, 122.6, 115.1 (d, <sup>2</sup>*J*<sub>C-F</sub> = 21.7 Hz), 110.9. <sup>19</sup>F NMR (CDCl<sub>3</sub>, 564.67MHz) δ -111.1. HPLC (chiral column: DAICEL CHIRALPAK IF; solvent: hexane/2-propanol = 49/1; flow rate: 1.0 mL/min; detection: at 254 nm):  $t_R = 8.9$  (major) and 10.8 (minor) min. HRMS (ESI) m/z: [M+H]<sup>+</sup> Calcd for C<sub>25</sub>H<sub>19</sub>FN<sub>3</sub>S<sup>+</sup>: 412.1278; Found 412.1284. [α]<sub>D</sub><sup>23.7</sup> = +138.9 (*c* = 0.50, CHCl<sub>3</sub>). Rf 0.43 (hexane/DCM = 1/3).




#### (S)-N,1,3-triphenyl-116-benzo[e][1,2,4]thiadiazin-1-imine (3ab)




**General Procedure** using compound **1a** (70.2 mg, 0.24 mmol) and **2b** (32.6 mg, 0.2 mmol) and purification by silica gel column chromatography (DCM/hexane = 2/1) afforded **3ab** as a colorless solid (55.6 mg, 71%). **<sup>1</sup>H NMR** (CDCl<sub>3</sub>, 600.17 MHz) δ 8.46-8.41 (m, 2H), 8.19-8.14 (m, 2H), 7.66-7.51 (m, 5H), 7.51-7.42 (m, 4H), 7.21-7.14 (m, 1H), 7.11-7.03 (m, 2H), 6.91-6.84 (m, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 150.92 MHz) δ 160.0, 150.0, 143.3, 141.7, 138.1, 134.2, 133.2, 130.8, 129.2, 129.1, 128.5, 128.3, 128.2, 128.2, 126.1, 125.3, 123.6,

122.6, 111.0. **HPLC** (chiral column: DAICEL CHIRALPAK IF; solvent: hexane/2-propanol = 49/1; flow rate: 1.0 mL/min; detection: at 254 nm):  $t_R = 10.1$  (major) and 12.6 (minor) min. **HRMS** (ESI) m/z:  $[M+H]^+$  Calcd for  $C_{25}H_{20}N_3S^+$ : 394.1372; Found 394.1373.  $[\alpha]_D^{23.3} = +130.1$  (c = 0.50, CHCl<sub>3</sub>). **Rf** 0.39 (hexane/AcOEt = 5/1).




#### (S)-N,1-diphenyl-3-(p-tolyl)-116-benzo[e][1,2,4]thiadiazin-1-imine (3ac)




General Procedure using compound 1a (70.2 mg, 0.24 mmol) and 2c (35.4 mg, 0.2 mmol) and purification by silica gel column chromatography (DCM/hexane = 3/2) afforded 3ac as a colorless solid (54.9 mg, 67%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600.17 MHz)  $\delta$  8.33 (d, *J* = 8.1 Hz, 2H), 8.19-8.12 (m, 2H), 7.65-7.55 (m, 3H), 7.55-7.49 (m, 2H), 7.47 (d, *J* = 7.9 Hz, 1H), 7.29-7.25 (m, 2H), 7.17-7.12 (m, 1H), 7.10-7.03 (m, 3H), 6.90-6.83 (m, 3H), 2.42 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 150.92 MHz)  $\delta$  159.9, 150.1, 143.3,

141.7, 141.1, 135.2, 134.1, 133.1, 129.1, 129.0, 128.9, 128.4, 128.3, 128.1, 125.8, 125.2, 123.6, 122.4, 110.8, 21.5 **HPLC** (chiral column: DAICEL CHIRALPAK IF; solvent: hexane/2-propanol = 49/1; flow rate: 1.0 mL/min; detection: at 254 nm):  $t_R = 11.5$  (major) and 13.6 (minor) min. **HRMS** (ESI) m/z: [M+H]<sup>+</sup> Calcd for C<sub>26</sub>H<sub>22</sub>N<sub>3</sub>S<sup>+</sup>: 408.1529; Found 408.1525. [ $\alpha$ ] $_{D}^{23.6} = +112.0$  (c = 0.50, CHCl<sub>3</sub>). **Rf** 0.51 (DCM/hexane = 3/1).




#### (S)-3-(4-methoxyphenyl)-N,1-diphenyl-116-benzo[e][1,2,4]thiadiazin-1-imine (3ad)




**General Procedure** using compound **1a** (70.2 mg, 0.24 mmol) and **2d** (38.6 mg, 0.2 mmol) and purification by silica gel column chromatography (DCM/hexane = 3/1) afforded **3ad** as a colorless solid (45.2 mg, 53%). <sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 600.17 MHz) δ 8.42-8.38 (m, 2H), 8.18-8.13 (m, 2H), 7.63-7.56 (m, 3H), 7.54-7.48 (m, 2H), 7.48-7.45 (m, 1H), 7.15-7.11 (m, 1H), 7.10-7.04 (m, 2H), 6.99-6.94 (m, 2H), 6.89-6.85 (m, 3H), 3.87 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} **NMR** (CDCl<sub>3</sub>, 150.92 MHz) δ 161.9, 159.6, 150.2,

143.4, 141.7, 134.1, 133.0, 130.5, 130.2, 129.1, 129.0, 128.3, 128.0, 125.6, 125.2, 123.5, 122.4, 113.4, 110.7, 55.3 **HPLC** (chiral column: DAICEL CHIRALPAK IF; solvent: hexane/2-propanol = 49/1; flow rate: 1.0 mL/min; detection: at 254 nm):  $t_R = 17.4$  (major) and 22.6 (minor) min. **HRMS** (ESI) m/z: [M+H]<sup>+</sup> Calcd for C<sub>26</sub>H<sub>22</sub>N<sub>3</sub>OS<sup>+</sup>: 424.1478; Found 424.1486. [ $\alpha$ ] $_{D}^{23.4} = +73.0$  (c = 0.50, CHCl<sub>3</sub>). **Rf** 0.1 (hexane/DCM = 1/3).




#### (S)-N,1-diphenyl-3-(4-(trifluoromethyl)phenyl)-1λ6-benzo[e][1,2,4]thiadiazin-1-imine (3ae)




General Procedure using compound 1a (70.2 mg, 0.24 mmol) and 2e (46.2 mg, 0.2 mmol) and purification by silica gel column chromatography (hexane/Et<sub>2</sub>O = 2/1) afforded 3ae as a colorless solid (90.1 mg, 97%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600.17 MHz)  $\delta$  8.54 (d, *J* = 8.2 Hz, 2H), 8.17-8.13 (m, 2H), 7.70 (d, *J* = 8.4 Hz, 2H), 7.66-7.60 (m, 3H), 7.58-7.54 (m, 2H), 7.50 (d, *J* = 7.7 Hz 1H), 7.24-7.19 (m, 1H), 7.10-7.05 (m, 2H), 6.89 (t, *J* = 7.4 Hz, 1H), 6.84 (d, *J* = 7.6 Hz, 2H). <sup>13</sup>C{<sup>1</sup>H} NMR

(CDCl<sub>3</sub>, 150.92 MHz)  $\delta$  158.4, 149.6, 143.0, 141.4, 141.3, 134.3, 133.3, 132.4 (q,  ${}^{2}J_{C-F} = 32.8$  Hz), 129.2, 129.1, 128.7, 128.4, 128.4, 126.8, 126.6, 125.2 (q,  ${}^{3}J_{C-F} = 3.9$  Hz), 124.3 (q,  ${}^{1}J_{C-F} = 272.0$  Hz), 123.6, 122.8, 111.3. <sup>19</sup>**F NMR** (CDCl<sub>3</sub>, 564.67MHz)  $\delta$  -63.27. **HPLC** (chiral column: DAICEL CHIRALPAK IA; solvent: hexane/2-propanol = 95/5; flow rate: 1.0 mL/min; detection: at 254 nm): t<sub>R</sub> = 7.1 (major) and 8.4 (minor) min. **HRMS** (ESI) m/z: [M+H]<sup>+</sup> Calcd for C<sub>26</sub>H<sub>19</sub>N<sub>3</sub>SF<sub>3</sub><sup>+</sup>: 462.1246; Found 462.1246. **[\alpha]<sub>D</sub><sup>23.0</sup> = +102.9 (***c* **= 0.50, CHCl<sub>3</sub>). <b>Rf** 0.45 (hexane/AcOEt = 5/1).




#### Methyl (S)-4-(1-phenyl-1-(phenylimino)-116-benzo[e][1,2,4]thiadiazin-3-yl)benzoate (3af)




General Procedure using compound 1a (70.2 mg, 0.24 mmol) and 2f (44.2 mg, 0.2 mmol) and purification by silica gel column chromatography (hexane/DCM/AcOEt = 8/1/1) afforded 3af as a colorless solid (54.8 mg, 61%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 399.78 MHz)  $\delta$  8.44-8.40 (m, 2H), 8.10-8.06 (m, 2H), 8.06-8.01 (m, 2H), 7.59-7.43 (m, 5H), 7.43-7.38 (m, 1H), 7.12 (ddd, J = 8.2, 6.5, 1.8 Hz, 1H), 7.02-6.96 (m, 2H), 6.83-6.74 (m, 3H), 3.86 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR

(CDCl<sub>3</sub>, 100.53 MHz)  $\delta$  166.9, 158.8, 149.6, 143.0, 141.6, 142.2, 141.3, 134.2, 133.3, 131.8, 129.4, 129.2, 129.1, 128.4, 128.3, 126.6, 125.3, 123.6, 122.7, 111.1, 52.2. **HPLC** (chiral column: DAICEL CHIRALPAK IF; solvent: hexane/2-propanol = 9/1; flow rate: 1.0 mL/min; detection: at 254 nm): t<sub>R</sub> = 11.7 (major) and 16.9 (minor) min. **HRMS** (APCI) m/z: [M+H]<sup>+</sup> Calcd for C<sub>27</sub>H<sub>22</sub>N<sub>3</sub>O<sub>2</sub>S<sup>+</sup>: 452.1427; Found 452.1432. [ $\alpha$ ] $_{D}^{23.7}$  = +71.8 (*c* = 1.0, CHCl<sub>3</sub>). **Rf** 0.28 (hexane/AcOEt = 3/1).




#### (S)-N,1-diphenyl-3-(m-tolyl)-116-benzo[e][1,2,4]thiadiazin-1-imine (3ag)




General Procedure using compound 1a (70.2 mg, 0.24 mmol) and 2g (35.4 mg, 0.2 mmol) and purification by silica gel column chromatography (DCM/hexane = 3/2) afforded 3ag as a colorless solid (52.8 mg, 65%).<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600.17 MHz)  $\delta$  8.27-8.21 (m, 2H), 8.18-8.13 (m, 2H), 7.64-7.54 (m, 4H), 7.54-7.50 (m, 1H), 7.47 (dd, J = 8.1, 1.2 Hz, 1H), 7.35 (t, J = 7.6 Hz, 1H), 7.30 (d, J = 7.2 Hz, 1H), 7.18-7.13 (m, 1H), 7.10-7.03 (m, 2H), 6.91-6.82 (m, 3H), 2.43 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 600.17 MR)

150.92 MHz) δ 160.1, 150.0, 143.3, 141.6, 137.9, 137.7, 134.1, 133.1, 131.6, 129.1, 129.0, 128.9, 128.4, 128.2, 128.1, 126.0, 125.6, 125.2, 123.5, 122.4, 110.8, 21.4 **HPLC** (chiral column: DAICEL CHIRALPAK IF; solvent: hexane/2-propanol = 49/1; flow rate: 1.0 mL/min; detection: at 254 nm):  $t_R = 9.3$  (major) and 11.5 (minor) min. **HRMS** (ESI) m/z: [M+H]<sup>+</sup> Calcd for C<sub>26</sub>H<sub>22</sub>N<sub>3</sub>S<sup>+</sup>: 408.1529; Found 408.1530. [*α*]<sub>D</sub><sup>23.3</sup> = +176.6 (*c* = 0.17, CHCl<sub>3</sub>). **Rf** 0.45 (DCM/hexane = 3/1).




#### (S)-3-(naphthalen-2-yl)-N,1-diphenyl-116-benzo[e][1,2,4]thiadiazin-1-imine (3ah)




**General Procedure** using compound **1a** (70.2 mg, 0.24 mmol) and **2h** (42.6 mg, 0.2 mmol) and purification by silica gel column chromatography (DCM/hexane = 3/2) afforded **3ah** as a colorless solid (71.9 mg, 81%).<sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 594.17 MHz)  $\delta$  8.96 (s, 1H), 8.57 (dd, *J* = 8.5, 1.7 Hz, 1H), 8.23-8.18 (m, 2H), 7.97 (d, *J* = 8.2 Hz, 1H), 7.92 (d, *J* = 8.2 Hz, 1H), 7.88 (d, *J* = 8.2 Hz, 1H), 7.64-7.60 (m, 4H), 7.57-7.47 (m, 4H), 7.20-7.17 (m, 1H), 7.08-7.05 (m, 2H), 6.91-6.85 (m, 3H). <sup>13</sup>C{<sup>1</sup>H} **NMR** 

(CDCl<sub>3</sub>, 149.41 MHz)  $\delta$  159.8, 150.0, 143.3, 141.6, 135.3, 134.8, 134.2, 133.2, 133.0, 129.2, 129.2, 129.1, 129.0, 128.5, 128.3, 127.7, 127.6, 127.1, 126.2, 126.1, 125.3, 123.6, 122.6, 111.1; one aromatic signal was missing probably due to overlapping. **HPLC** (chiral column: DAICEL CHIRALPAK IF; solvent: hexane/2-propanol = 49/1; flow rate: 1.0 mL/min; detection: at 254 nm): t<sub>R</sub> = 12.7 (major) and 18.9 (minor) min. **HRMS** (ESI) m/z: [M+H]<sup>+</sup> Calcd for C<sub>29</sub>H<sub>22</sub>N<sub>3</sub>S<sup>+</sup>: 444.1529; Found 444.1537.  $[\alpha]_{p}^{23.3} = +51.4$  (*c* = 0.16, CHCl<sub>3</sub>). **Rf** 0.45 (DCM/hexane = 3/1).




#### (S)-3-(furan-2-yl)-N,1-diphenyl-116-benzo[e][1,2,4]thiadiazin-1-imine (3ai)




**General Procedure** using compound **1a** (70.2 mg, 0.24 mmol) and **2i** (30.6 mg, 0.2 mmol) and purification by silica gel column chromatography (hexane/AcOEt = 6/1) afforded **3ai** as a colorless solid (39.2 mg, 51%). <sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 600.17 MHz) δ 8.20-8.12 (m, 2H), 7.65-7.56 (m, 5H), 7.54-7.48 (m, 1H), 7.47-7.42 (m, 1H), 7.26 (d, *J* = 3.4 Hz, 1H), 7.17-7.14 (m, 1H), 7.11-7.06 (m, 2H), 6.92-6.84 (m, 3H), 6.54 (dd, *J* = 3.4, 1.7 Hz, 1H). <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 150.92 MHz) δ 152.5, 151.6, 149.7, 145.1, 143.0, 141.4, 134.3, 133.2, 129.2, 129.0,

128.5, 128.1, 126.1, 125.3, 123.5, 122.6, 114.4, 111.9, 111.5 **HPLC** (chiral column: DAICEL CHIRALPAK IA; solvent: hexane/2-propanol = 95/5; flow rate: 1.0 mL/min; detection: at 254 nm):  $t_R = 20.3$  (major) and 22.2 (minor) min. **HRMS** (ESI) m/z: [M+H]<sup>+</sup> Calcd for C<sub>23</sub>H<sub>18</sub>N<sub>3</sub>OS<sup>+</sup>: 384.1165; Found 384.1163. [ $\alpha$ ] $_{D}^{23.1} = +132.2$  (c = 0.22, CHCl<sub>3</sub>). **Rf** 0.14 (DCM/hexane = 3/1).




#### (S)-N,1-diphenyl-3-(thiophen-2-yl)-116-benzo[e][1,2,4]thiadiazin-1-imine (3aj)




**General Procedure** using compound **1a** (70.2 mg, 0.24 mmol) and **2j** (33.8 mg, 0.2 mmol) and purification by silica gel column chromatography (DCM/hexane = 3/2) afforded **3aj** as a colorless solid (47.5 mg, 60%). <sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 600.17 MHz) δ 8.19-8.14 (m, 2H), 7.98-7.91 (m, 1H), 7.63-7.58 (m, 3H), 7.52-7.42 (m, 4H), 7.15-7.07 (m, 4H), 6.93-6.87 (m, 3H). <sup>13</sup>C{<sup>1</sup>**H**} **NMR** (CDCl<sub>3</sub>, 150.92 MHz) δ 156.2, 149.9, 143.9, 143.1, 141.5, 134.2, 133.2, 130.0, 129.5, 129.2, 129.0, 128.4, 127.8, 127.8, 125.8, 125.3, 123.7, 122.7, 111.2 **HPLC** 

(chiral column: DAICEL CHIRALPAK IA; solvent: hexane/2-propanol = 95/5; flow rate: 1.0 mL/min; detection: at 254 nm):  $t_R = 13.6$  (major) and 17.5 (minor) min. **HRMS** (ESI) m/z:  $[M+H]^+$  Calcd for  $C_{23}H_{18}N_3S_2^+$ : 400.0937; Found 400.0926. [ $\alpha$ ] $_{D}^{23.2} = +106.8$  (c = 0.50, CHCl<sub>3</sub>). **Rf** 0.39 (DCM/hexane = 3/1).




#### (S,E)-N,1-diphenyl-3-styryl-116-benzo[e][1,2,4]thiadiazin-1-imine (3ak)




**General Procedure** using compound **1a** (70.2 mg, 0.24 mmol) and **2k** (37.8 mg, 0.2 mmol) and purification by silica gel column chromatography (DCM/hexane = 3/1) afforded **3ak** as a colorless solid (39.1 mg, 47%). <sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 599.67 MHz)  $\delta$  8.14 (d, J = 7.5 Hz, 2H), 7.89 (d, J = 15.8 Hz, 1H), 7.64-7.57 (m, 6H), 7.50 (t, J = 7.2 Hz, 1H), 7.45 (d, J = 7.5 Hz, 1H), 7.38-7.33 (m, 2H), 7.33-7.29 (m, 1H), 7.15 (t, J = 6.9 Hz, 1H), 7.12-7.06 (m, 3H), 6.91-6.85 (m, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 149.41

MHz)  $\delta$  160.2, 142.9, 141.3, 139.3, 135.7, 134.5, 133.4, 129.3, 129.2, 128.8, 128.5, 127.9, 127.0, 126.4, 125.4, 123.6, 122.8, 111.7; three aromatic signals were missing probably due to overlapping and broadened signals. **HPLC** (chiral column: DAICEL CHIRALPAK IA; solvent: hexane/2-propanol = 95/5; flow rate: 1.0 mL/min; detection: at 254 nm): t<sub>R</sub> = 19.2 (major) and 27.1 (minor) min. **HRMS** (ESI) m/z: [M+H]<sup>+</sup> Calcd for C<sub>27</sub>H<sub>22</sub>N<sub>3</sub>S<sup>+</sup>: 420.1529; Found 420.1538. **[a]** $_{D}^{23.1}$  = +22.9 (*c* = 0.12, CHCl<sub>3</sub>). **Rf** 0.35 (DCM/hexane = 3/1).




#### (S)-3-methyl-N,1-diphenyl-116-benzo[e][1,2,4]thiadiazin-1-imine (3al)




General Procedure using compound 1a (70.2 mg, 0.24 mmol) and 2l (20.2  $\mu$ l, 0.2 mmol) and purification by silica gel column chromatography (hexane/AcOEt = 2/1) afforded 3al as a colorless solid (45.0 mg, 68%).<sup>1</sup>H NMR (CDCl<sub>3</sub>, 600.17 MHz)  $\delta$  8.10 (d, *J* = 7.9 Hz, 2H), 7.64-7.59 (m, 3H), 7.50 (t, *J* = 7.7 Hz, 1H), 7.45-7.35 (m,, 2H), 7.18-7.08 (m, 3H), 6.92 (t, *J* = 7.4 Hz, 1H), 6.81 (d, *J* = 8.2 Hz, 2H), 2.49 (s, 3H).<sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 150.92 MHz)  $\delta$  164.0,

149.4, 143.1, 141.2, 134.2, 133.2, 129.1, 129.0, 128.3, 127.1, 125.9, 125.2, 123.5, 122.5, 110.2, 27.9 **HPLC** (chiral column: DAICEL CHIRALPAK IA; solvent: hexane/2-propanol = 95/5; flow rate: 1.0 mL/min; detection: at 254 nm):  $t_R = 15.6$  (major) and 18.2 (minor) min. **HRMS** (ESI) m/z:  $[M+H]^+$  Calcd for  $C_{20}H_{18}N_3S^+$ : 332.1216; Found 332.1219.  $[\alpha]_D^{22.8} = +232.2$  (c = 0.25, CHCl<sub>3</sub>). **Rf** 0.14 (DCM/hexane = 3/1).




#### (S)-6-methyl-N,3-diphenyl-1-(p-tolyl)-116-benzo[e][1,2,4]thiadiazin-1-imine (3bb)




**General Procedure** using compound **1b** (76.9 mg, 0.24 mmol) and **2b** (32.6 mg, 0.20 mmol) and purification by silica gel column chromatography (hexane/AcOEt = 10/1) afforded **3bb** as a colorless solid (62.3 mg, 74%). <sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 600.17 MHz) δ 8.45-8.39 (m, 2H), 8.00 (d, *J* = 8.2 Hz, 2H), 7.51-7.42 (m, 3H), 7.40-7.33 (m, 4H), 7.09-7.03 (m, 2H), 6.97 (d, *J* = 8.2 Hz, 1H), 6.90-6.82 (3H, m), 2.44 (s, 3H), 2.36 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 150.92 MHz) δ 159.9, 149.9, 144.9, 144.0, 143.5, 138.9,

138.1, 130.6, 129.7, 128.9, 128.3, 128.2, 128.0, 127.8, 127.5, 124.9, 123.5, 122.2, 108.3, 21.6, 21.4. **HPLC** (chiral column: DAICEL CHIRALPAK IF; solvent: hexane/2-propanol = 49/1; flow rate: 1.0 mL/min; detection: at 254 nm):  $t_R = 11.9$  (major) and 19.7 (minor) min. **HRMS** (ESI) m/z:  $[M+H]^+$  Calcd for  $C_{27}H_{24}N_3S^+$ : 422.1685; Found 422.1682.  $[\alpha]_D^{22.9} = +133.6$  (c = 0.50, CHCl<sub>3</sub>). **Rf** 0.23 (DCM/hexane = 3/1).




#### (S)-6-chloro-1-(4-chlorophenyl)-N,3-diphenyl-116-benzo[e][1,2,4]thiadiazin-1-imine (3cb)




General Procedure using compound 1c (86.7 mg, 0.24 mmol) and 2b (32.6 mg, 0.20 mmol) and purification by silica gel column chromatography (hexane/AcOEt = 40/1) afforded 3cb as a colorless solid (73.8 mg, 80%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600.17 MHz)  $\delta$  8.43-8.38 (m, 2H), 8.09-8.04 (m, 2H), 7.58-7.55 (m, 3H), 7.53-7.49 (m, 1H), 7.49-7.45 (m, 2H), 7.38 (d, *J* = 8.2 Hz, 1H), 7.13 (dd, *J* = 8.6, 2.1 Hz, 1H), 7.11-7.07 (2H, m), 6.93-6.89 (m, 1H), 6.86-6.82 (m, 2H).<sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 150.92 MHz)  $\delta$  160.7,

151.2, 142.5, 140.3, 140.2, 139.8, 137.4, 131.2, 129.8, 129.5, 129.2, 128.5, 128.2, 127.7, 126.6, 126.4, 123.5, 123.0, 109.0. **HPLC** (chiral column: DAICEL CHIRALPAK IF; solvent: hexane/2-propanol = 49/1; flow rate: 1.0 mL/min; detection: at 254 nm):  $t_R = 7.7$  (major) and 12.5 (minor) min. **HRMS** (ESI) m/z: [M+H]<sup>+</sup> Calcd for C<sub>25</sub>H<sub>18</sub>Cl<sub>2</sub>N<sub>3</sub>S<sup>+</sup>: 462.0593; Found 462.0599. [ $\alpha$ ] $_{D}^{22.9}$  = +107.5 (*c* = 0.50, CHCl<sub>3</sub>). **Rf** 0.43 (DCM/hexane = 3/1).




#### (S)-N,3-diphenyl-6-(trifluoromethyl)-1-(4-(trifluoromethyl)phenyl)-116-benzo[e][1,2,4]thiadiazin-1-imine

(3db)




General Procedure using compound 1d (102.8 mg, 0.24 mmol) and 2b (32.6 mg, 0.20 mmol) and purification by silica gel column chromatography (hexane/AcOEt = 40/1) afforded 3db as a colorless solid (93.8 mg, 89%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600.17 MHz)  $\delta$  8.46-8.40 (m, 2H), 8.29 (d, *J* = 8.6 Hz, 2H), 7.91-7.84 (m, 3H), 7.58 (d, *J* = 8.2 Hz, 1H), 7.55-7.51 (m, 1H), 7.51-7.46 (m, 2H), 7.38 (dd, *J* = 8.6, 1.7 Hz, 1H),

7.14-7.09 (m, 2H), 6.96-6.92 (m, 1H), 6.89-6.84 (m, 2H). <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 150.92 MHz)  $\delta$  160.9, 150.5, 144.5, 142.1, 137.1, 136.1 (q, <sup>2</sup>*J*<sub>C-F</sub> = 33.2 Hz), 135.1 (q, <sup>2</sup>*J*<sub>C-F</sub> = 33.2 Hz), 131.5, 129.3, 129.1, 128.6, 128.3, 126.5 (q, <sup>3</sup>*J*<sub>C-F</sub> = 3.9 Hz), 126.2, 126.1 (q, <sup>3</sup>*J*<sub>C-F</sub> = 3.9 Hz), 123.6, 123.4, 123.0 (q, <sup>1</sup>*J*<sub>C-F</sub> = 273.6 Hz), 123.0 (q, <sup>1</sup>*J*<sub>C-F</sub> = 273.6 Hz), 122.9 (q, <sup>3</sup>*J*<sub>C-F</sub> = 3.4 Hz), 113.2. <sup>19</sup>F NMR (CDCl<sub>3</sub>, 564.67MHz)  $\delta$  -63.2, -63.8. HPLC (chiral column: DAICEL CHIRALPAK IF; solvent: hexane/2-propanol = 49/1; flow rate: 1.0 mL/min; detection: at 254 nm): t<sub>R</sub> = 4.1 (major) and 7.3 (minor) min. HRMS (ESI) m/z: [M+H]<sup>+</sup> Calcd for C<sub>27</sub>H<sub>18</sub>F<sub>6</sub>N<sub>3</sub>S<sup>+</sup>: 530.1120; Found 530.1122. [*α*]<sub>D</sub><sup>22.9</sup> = +66.5 (*c* = 0.50, CHCl<sub>3</sub>). Rf 0.43 (DCM/hexane = 3/1).




#### (S)-7-methyl-N,3-diphenyl-1-(m-tolyl)-116-benzo[e][1,2,4]thiadiazin-1-imine (3eb)




General Procedure using compound 1e (76.9 mg, 0.24 mmol) and 2b (32.6 mg, 0.20 mmol) and purification by silica gel column chromatography (hexane/AcOEt = 40/1) afforded 3eb as a colorless solid (70.6 mg, 84%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600.17 MHz)  $\delta$  8.44-8.37 (m, 2H), 7.95 (d, *J* = 7.9, 1H), 7.93 (s, 1H), 7.50-7.42 (m, 5H), 7.41 (d, *J* = 7.2 Hz, 1H), 7.34 (d, *J* = 7.9 Hz, 1H), 7.23 (s, 1H), 7.10-7.04 (m, 2H), 6.89-6.83 (m, 3H), 2.45 (s, 3H), 2.27 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 150.92 MHz)

δ 159.1, 147.8, 143.4, 141.5, 139.4, 138.0, 136.2, 135.6, 133.9, 130.5, 129.0, 128.9, 128.5, 128.3, 128.0, 127.9, 125.6, 124.3, 123.4, 122.2, 110.5, 21.4, 21.0. **HPLC** (chiral column: DAICEL CHIRALPAK IF; solvent: hexane/2-propanol = 49/1; flow rate: 1.0 mL/min; detection: at 254 nm): t<sub>R</sub> = 8.8 (major) and 13.3 (minor) min. **HRMS** (ESI) m/z: [M+H]<sup>+</sup> Calcd for C<sub>27</sub>H<sub>24</sub>N<sub>3</sub>S<sup>+</sup>: 422.1685; Found 422.1684. [*α*]<sub>D</sub><sup>22.9</sup> = +146.5 (*c* = 0.50, CHCl<sub>3</sub>). **Rf** 0.30 (DCM/hexane = 3/1).




#### (S)-N-(4-methoxyphenyl)-1,3-diphenyl-116-benzo[e][1,2,4]thiadiazin-1-imine (3fb)




General Procedure using compound 1f (77.4 mg, 0.24 mmol) and 2b (32.6 mg, 0.20 mmol) and purification by silica gel column chromatography (hexane/DCM= 1/1) afforded 3fb as a colorless solid (24.9 mg, 30%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600.17 MHz)  $\delta \delta 8.43$  (d, J = 5.5 Hz, 2H), 8.15 (J = 7.2 Hz, 2H), 7.66-7.56 (m, 3H), 7.56-7.51 (m, 2H), 7.51-7.41 (m, 4H), 7.22-7.13 (m, 1H), 6.81 (d, J = 8.6 Hz, 2H), 6.62 (d, J = 8.6 Hz, 2H), 3.65 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 150.92 MHz)  $\delta$  160.0, 155.4, 150.1, 141.5, 138.1, 136.0, 134.1, 133.1, 130.8, 129.2, 128.5, 128.3, 128.2,

126.0, 125.3, 124.8, 114.4, 112.8, 111.1, 55.3. **HPLC** (chiral column: DAICEL CHIRALPAK IF; solvent: hexane/2propanol = 49/1; flow rate: 1.0 mL/min; detection: at 254 nm):  $t_R = 17.9$  (major) and 25.6 (minor) min. **HRMS** (ESI) m/z: [M+H]<sup>+</sup> Calcd for C<sub>26</sub>H<sub>22</sub>N<sub>3</sub>OS<sup>+</sup>: 424.1478; Found 424.1478. [ $\alpha$ ] $_D^{22.9} = +633.8$  (c = 0.17, CHCl<sub>3</sub>). **Rf** 0.13 (hexane/DCM= 1/3).




#### (S)-N-(4-chlorophenyl)-1,3-diphenyl-116-benzo[e][1,2,4]thiadiazin-1-imine (3gb)




General Procedure using compound 1g (78.4 mg, 0.24 mmol) and 2b (32.6 mg, 0.20 mmol) and purification by silica gel column chromatography (hexane/AcOEt = 10/1) afforded 3gb as a colorless solid (29.7 mg, 35%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600.17 MHz)  $\delta$  8.44-8.40 (m, 2H), 8.15-8.12 (m, 2H), 7.64-7.53 (m, 5H), 7.51-7.42 (m, 4H), 7.21-7.16 (m, 1H), 7.05-6.99 (m, 2H), 6.81-6.75 (m, 2H). <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 150.92 MHz)  $\delta$  160.0, 150.0, 142.0, 141.3, 137.8, 134.3, 133.3, 131.0, 129.3, 129.1, 128.4, 128.4, 128.2, 127.9, 126.2, 125.1, 124.8, 110.5; one aromatic signal was missing

probably due to overlap. **HPLC** (chiral column: DAICEL CHIRALPAK IF; solvent: hexane/2-propanol = 49/1; flow rate: 1.0 mL/min; detection: at 254 nm):  $t_R = 9.3$  (major) and 11.5 (minor) min. **HRMS** (ESI) m/z:  $[M+H]^+$  Calcd for C<sub>25</sub>H<sub>19</sub>N<sub>3</sub>SCl<sup>+</sup>: 428.0983; Found 428.0970.  $[\alpha]_D^{22.7} = +88.2$  (c = 0.20, CHCl<sub>3</sub>). **Rf** 0.45 (hexane/EtOAc = 5/1).




#### (S)-N-(3-chlorophenyl)-1,3-diphenyl-116-benzo[e][1,2,4]thiadiazin-1-imine (3hb)




**General Procedure** using compound **1h** (78.4 mg, 0.24 mmol) and **2b** (32.6 mg, 0.20 mmol) and purification by silica gel column chromatography (hexane/AcOEt = 10/1) afforded **3hb** as a colorless solid (69.1 mg, 81%). <sup>1</sup>**H NMR** (CDCl<sub>3</sub>, 600.17 MHz)  $\delta$  8.46-8.41 (m, 2H), 8.16-8.11 (m, 2H), 7.67-7.53 (m, 5H), 7.53-7.44 (m, 4H), 7.22-7.18 (m, 1H), 7.01 (t, *J* = 2.0 Hz, 1H), 6.94 (t, *J* = 8.0 Hz, 1H), 6.88-6.83 (m, 1H), 6.63-6.59 (m, 1H). <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 150.92 MHz)  $\delta$  159.7, 149.8, 144.8, 141.3, 137.8, 134.4, 134.3, 133.3, 130.9, 129.9, 129.2, 128.4, 128.4, 128.3, 128.2, 126.3, 125.1, 124.6, 122.6, 120.8, 110.4. **HPLC** (chiral column: DAICEL CHIRALPAK IF; solvent:

hexane/2-propanol = 49/1; flow rate: 1.0 mL/min; detection: at 254 nm):  $t_R = 8.8$  (major) and 11.5 (minor) min. HRMS (ESI) m/z: [M+H]<sup>+</sup> Calcd for C<sub>25</sub>H<sub>19</sub>N<sub>3</sub>SCl<sup>+</sup>: 428.0983; Found 428.0978. [ $\alpha$ ] $_D^{22.8}$  = +86.7 (*c* = 0.50, CHCl<sub>3</sub>). Rf 0.45 (hexane/EtOAc = 5/1).




#### (S)-N-(2-chlorophenyl)-1,3-diphenyl-116-benzo[e][1,2,4]thiadiazin-1-imine (3ib)



General Procedure using compound 1i (78.4 mg, 0.24 mmol) and 2b (32.6 mg, 0.20 mmol) and purification by silica gel column chromatography (hexane/AcOEt = 10/1) afforded **3ib** as a colorless solid (67.3 mg, 79%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600.17 MHz)  $\delta$  8.51-8.44 (m, 2H), 8.32-8.22 (m, 2H), 7.70-7.58 (m, 3H), 7.58-7.45 (m, 6H), 7.30 (dd, *J* = 7.8, 1.5 Hz, 1H), 7.21-7.13 (m, 1H), 6.84 (td, *J* = 7.6, 1.5 Hz, 1H), 6.80 (td, *J* = 7.6, 1.5 Hz, 1H), 6.68 (dd, *J* = 7.9, 1.5 Hz, 1H). <sup>13</sup>C{<sup>1</sup>H} NMR (CDCl<sub>3</sub>, 150.92 MHz)  $\delta$  159.5, 150.0,

141.7, 140.6, 137.8, 134.4, 133.4, 131.0, 130.0, 130.0, 129.3, 128.7, 128.5, 128.2, 127.2, 126.3, 125.3, 123.3, 122.3, 110.3; one aromatic signal was missing probably due to overlap. **HPLC** (chiral column: DAICEL CHIRALPAK IF; solvent: hexane/2-propanol = 49/1; flow rate: 1.0 mL/min; detection: at 254 nm):  $t_R = 7.8$  (major) and 8.6 (minor) min. **HRMS** (ESI) m/z:  $[M+H]^+$  Calcd for C<sub>25</sub>H<sub>19</sub>N<sub>3</sub>SCl<sup>+</sup>: 428.0983; Found 428.0974.  $[\alpha]_D^{22.8} = +51.9$  (c = 0.50, CHCl<sub>3</sub>). **Rf** 0.45 (hexane/EtOAc = 5/1).



### **2-3. Determination of the absolute configuration of 3aa** Single crystal X-ray crystallography of 3aa

A single crystal of **3aa** suitable for X-ray diffraction analysis (XRD) was obtained by recrystallization from pentane/DCE. Measurement was performed on a RIGAKU XtaLAB Synergy-R/Cu system with 1.2 kW PhotonJet-R/Cu microfocus rotating anode using graphite monochromated CuK $\alpha$  radiation source ( $\lambda = 1.5418$  Å) and HyPix-6000HE detector. Cell parameters were determined and refined, and raw frame data were integrated using CrysAlisPro (Agilent Technologies, 2010). The structures were solved by direct methods with SHELXT 2018/2 and refined by full-matrix least-squares techniques against  $F^2$  with SHELXL-2019/3 by using Olex2 software package. The non-hydrogen atoms were anisotropically refined, and hydrogen atoms were placed using AFIX instructions. The detailed crystallographic data are available as a crystallographic information file (CIF), which is available from CCDC (Deposition Number: 2423806). The ORTEP-3 program was used to draw the molecule structures. The structure and crystal data are shown in **Figure S1** and **Table S1**.




Figure S1. Structure of 3aa

#### Table S1. Crystal data and structure refinement for 3aa

Identification code	am02046_auto	
Empirical formula	C25 H18 F N3 S	
Formula weight	411.48	
Temperature	100.00(10) K	
Wavelength	1.54184 Å	
Crystal system	Monoclinic	
Space group	P 1 21 1	
Unit cell dimensions	a = 8.40678(5)  Å	a= 90°.
	b = 12.62273(9) Å	b=91.4256(5)°.
	c = 18.65018(10) Å	g = 90°.
Volume	1978.48(2) Å <sup>3</sup>	
Ζ	4	
Density (calculated)	1.381 Mg/m <sup>3</sup>	
Absorption coefficient	1.667 mm <sup>-1</sup>	

F(000)	856
Crystal size	0.2 x 0.15 x 0.15 mm <sup>3</sup>
Theta range for data collection	2.370 to 78.783°.
Index ranges	-10<=h<=10, -15<=k<=14, -23<=l<=23
Reflections collected	78131
Independent reflections	8270 [R(int) = 0.0403]
Completeness to theta = $67.684^{\circ}$	100.0 %
Absorption correction	Semi-empirical from equivalents
Max. and min. transmission	1.00000 and 0.70830
Refinement method	Full-matrix least-squares on F <sup>2</sup>
Data / restraints / parameters	8270 / 1 / 541
Goodness-of-fit on F <sup>2</sup>	1.027
Final R indices [I>2sigma(I)]	R1 = 0.0360, wR2 = 0.0955
R indices (all data)	R1 = 0.0362, wR2 = 0.0957
Absolute structure parameter	0.023(11)
Extinction coefficient	n/a
Largest diff. peak and hole	0.720 and -0.457 e.Å <sup>-3</sup>

#### 3. DFT calculations and non-covalent interaction plots.

All DFT calculations and structure optimizations were performed using Gaussian 16 Rev C.02 program package<sup>[S5]</sup> unless otherwise noted.

Cp\*Co(III)-catalyzed C-H activation generally proceed with an assistance of directing groups such as a imine group in sulfondimines. We initially performed DFT calculations to elucidate a spin state in the transition state and whether N-H or N-aryl group is coordinating to the cobalt center in the transition state. We first prepared 4 transition states that possess  $\mu^1$ -acetate and NH-coordinating sulfondiimine or NPh-coordinating sulfondiimine on the cobalt center (s NH, s NPh for the metallacycle with (S)-configuration, r NH, r NPh for the metallacycle with (R)configuration). The structures were roughly optimized as the singlet and triplet states at the (U)M06L/def2-SVP<sup>[S6]</sup> level of theory with the fixed key 6 atoms (Co, C and H to be cleaved, carbonyl C and two O of the carboxylate). These structures were fully optimized to transition state structures (first-order saddle points) at the (U)M06L/def2-SVP level of theory. The vibrational calculations were performed at the optimized geometry to confirm that the obtained structures were the desired transition state structures and to calculate the correction terms for Gibbs free energies. To obtain more accurate electronic energies, single point energies with the optimized geometries were calculated at the (U)M06/def2-TZVPP<sup>[S7]</sup> level of theory with SMD implicit solvation (solvent = 2-methyl-2propanol).<sup>[S8]</sup> The Gibbs free energies are summarized in Table S2. In all transition states, the singlet states were more stable than the corresponding triplet states. The singlet s NH was the most stable, but the differences of Gibbs free energies with the singlet NPh-coordinating structures were not negligible. As all the triplet states showed significantly higher energies than the corresponding singlet states, the following calculations were performed assuming the singlet states.




Figure S2. Comparison of transition state Gibbs energies (kcal/mol) of the singlet and triplet states

Table S2. Parameters of TS structures					
	EE (M06/def2-	Imaginary	G correction	G	Relative G to
	TZVPP+SMD(t	Frequency	term	(Hartrees)	s_NH
	BuOH))	$(cm^{-1})$	(Hartrees)		(kcal/mol)
	(Hartrees)				
singlet_s_NH	-3203.86426685	-1525.0895	0.500237	-3203.36403	0
singlet_r_NH	-3203.85670938	-1436.4002	0.498308	-3203.358401	3.531921
singlet_s_NPh	-3203.86157585	-1443.3729	0.501826	-3203.35975	2.685743
singlet r_NPh	-3203.86002976	-1436.3116	0.500388	-3203.359642	2.75357
triplet_s_NH	-3203.8485254	-1473.9925	0.492401	-3203.356124	4.960749

triplet_r_NH	-3203.84283027	-1286.1958	0.494282	-3203.348548	9.714846
triplet_s_NPh	-3203.85052069	-1202.8165	0.497972	-3203.352549	7.204543
triplet_r_NPh	-3203.84832575	-1522.0098	0.494951	-3203.353375	6.686182

To reveal the key effects of A5 on high enantioselectivity in the transition state, we carried out DFT calculation for the asymmetric reaction. We prepared eight initial structures (r1\_NH\_init, r1\_NPh\_init, r2\_NH\_init, r2\_NPh\_init for the cyclized product with (R)-configuration, s1\_NH\_init, s1\_NPh\_init, s2\_NH\_init, s2\_NPh\_init for the cyclized product with (S)-configuration shown in **Figure S3**) that possess a common key core structure near to the transition state for the C–H bond cleavage (optimized as a singlet state near to the first-order saddle point at the M06L/LANL2DZ level of theory,<sup>[S9,S10]</sup> but not completely converged).




Figure S3. Initial structures for conformation searches

With these initial structures, we performed conformational searches using Grimme's crest  $2.12^{[S11]}$  and xtb  $6.6.1^{[S12]}$  programs. To keep the structures near to the desired transition state rather than local minima, key 6 atoms (Co, C and H to be cleaved, carbonyl C and two O of the carboxylate) were fixed with a force constant = 0.5. The

conformation searches were run at GFN2-xTB level with iMTD-GC algorithm, and the energy threshold was set to 10 kcal/mol for each search. Total 2391 conformers to afford the (*S*)-configuration product and 3013 conformers to afford the (*R*)-configuration product were generated. The conformers obtained from r1\_NPh\_init, r2\_NH\_init, s1\_NH\_init, and s2\_NPh\_init are 5.0 kcal/mol higher in energy than the most stable conformer obtained from  $s2_NH_init$ , and thus only the most stable conformer of each initial structure was used for further calculations. To further reduce the calculation cost, the similar conformers were summarized using cregen tool implemented in crest (ewin 6, rthr 1, ethr 2), and total 19 conformers remained. These structures were partially optimized with fixing key 6 atoms (Co, C and H to be cleaved, two O of the carboxylate) at the M06L/LANL2DZ level of theory (opt = loose, maxcycle = 20). These structures were fully optimized to transition state structures (first-order saddle points) at the M06L/def2-SVP level of theory. The vibrational calculations were performed at the optimized geometry to confirm that the obtained structures were the desired transition state structures and to calculate the correction terms for Gibbs free energies. To obtain more accurate electronic energies, single point energies with the optimized geometries were calculated at the M06/def2-TZVPP level of theory with SMD implicit solvation (solvent = 2-methyl-2-propanol). The calculated free energies of the final 19 transition state structures are summarized in **Table S3** and **S4**.

Based on the calculated free energies,  $s2_NH_2$  was the most plausible transition state structure to give the major *S*-enantiomer (TS<sub>major1</sub>), and  $s2_NH_1$  afford the second most stable structure (TS<sub>major2</sub>).  $s2_NH_3$  had very similar structure and Gibs energy that are enough to be regarded as the same as  $s2_NH_1$ . Other structures could be negligible.  $r2_NPh_1$  was the most stable structure to afford the minor product with (*R*)-configuration (TS<sub>minor</sub>), and other structures could be negligible. Thus, we provided the discussion based on  $s2_NH_2$  (TS<sub>major1</sub>) and  $s2_NH_1$  (TS<sub>major2</sub>).  $r2_NPh_1$  (TS<sub>minor</sub>) was the most plasible transition state structures to give the minor (*R*)-enantiomer. For these three structures, IRC calculations were performed at the M06L/def2-SVP level of theory to confirm that they are the desired transition states for C–H bond cleavage. NCI plots were calculated by Multiwfn  $3.7^{[S13]}$  using the wavefunction files (wfx files) generated at the single point energy calculations (M06/def2-TZVPP+SMD(*t*BuOH)), and visualized by VMD 1.9.4 (**Figure 15**).<sup>[S14]</sup>

	EE (M06/def2-	Imaginary	G correction	G	Relative G to
	TZVPP+SMD	Frequency	term	(Hartrees)	s2_NH_2
	(tBuOH))	$(cm^{-1})$	(Hartrees)		(kcal/mol)
	(Hartrees)				4 - 0
s1_NH	-4385.35567878	-1502.5	0.933146	-	4.50
				4384.42253278	
s1_NPh_1	-4385.35986930	-1464.52	0.935711	- 4384.42415830	3.48
				-	
s1_NPh_2	-4385.35751284	-1462.81	0.937081	4384.42043184	5.82
s1 NPh 3	-4385.35696306	-1445.27	0.934814	-	4.74
31_1111_5	-+505.55070500	-1443.27	0.954014	4384.42214906	7.77
s1 NPh 4	-4385.34992871	-1426.63	0.933346	- 4384.41658271	8.24
				4384.41038271	
s1_NPh_5	-4385.35377113	-1456.17	0.934992	4384.41877913	6.86
s2 NH 1	-4385.35805015	-1455.31	0.931495	-4384.42655515	1.98
(similar to					
s2_NH_3)					
s2_NH_2	-4385.36412869	-1448.92	0.934421	-4384.42970769	0.00
s2_NH_3	-4385.35805017	-1455.32	0.931495	-4384.42655517	1.98

Table S3. Parameters of TS structures to afford major S-product

s2 NPh -4385.35714304 -1470.98 0.934714 -4384.42242904 4	s2 NPh
--	--------

Table S4. Parameters of TS structures to give minor R-product					
	EE (M06/def2-	Imaginary	G correction	G	Relative G to
	TZVPP+SMD(t	Frequency	term	(Hartrees)	s2_NH_2
	BuOH))	$(cm^{-1})$	(Hartrees)		(kcal/mol)
	(Hartrees)				
r1_NH_1	-4385.35079584	-1487.81	0.931330	-4384.41946584	6.43
r1_NH_2	-4385.34934015	-1445.65	0.931953	-4384.41738715	7.73
r1_NH_3	-4385.34627232	-1434.68	0.931286	-4384.41498632	9.24
r1_NH_4	-4385.34419791	-1433.5	0.931336	-4384.41286191	10.57
r1_NPh	-4385.35745525	-1441.73	0.934678	-4384.42277725	4.35
r2_NH	-4385.35820841	-1509.26	0.934163	-4384.42404541	3.55
r2_NPh_1	-4385.36036832	-1441.6	0.934436	-4384.42593232	2.37
r2_NPh_2	-4385.35713533	-1466.75	0.934534	-4384.42260133	4.46
r2_NPh_3	-4385.35370708	-1440.37	0.934710	-4384.41899708	6.72

Table S4. Parameters of TS structures to give minor *R*-product

#### 4. Reference

[S1] Huang, L.-T.; Kitakawa, Y.; Yamada, K.; Kamiyama, F.; Kojima, M; Yoshino, T.; Matsunaga, S. *Angew. Chem. Int. Ed.* **2023**, *62*, e202305480.

[S2] J. Park, S. Chang, Angew. Chem. Int. Ed. 2015, 54, 14103.

- [S3] a) S. Fukagawa, Y. Kato, R. Tanaka, M. Kojima, T. Yoshino, S. Matsunaga, Angew. Chem. Int. Ed. 2019, 58,
- 1153; b) D. Sekine, K. Ikeda, S. Fukagawa, M. Kojima, T. Yoshino, S. Matsunaga, Organometallics 2019, 38, 3921;
- c) L. Lin, S. Fukagawa, D. Sekine, E. Tomita, T. Yoshino, S. Matsunaga, Angew. Chem. Int. Ed. 2018, 57, 12048;
- d) Y. Kato, L. Lin, M. Kojima, T. Yoshino, S. Matsunaga, ACS Catal. 2021, 11, 4271; e) Hirata, Y.; Sekine, D.; Kato,
- Y.; Lin, L.; Kojima, M.; Yoshino, T.; Matsunaga, S. Angew. Chem. Int. Ed. 2022, 61, e202205341.
- [S4] B. Sun, T. Yoshino, S. Matsunaga, M. Kanai, Adv. Synth. Catal. 2014, 356, 1491.
- [S5] Gaussian 16, Revision C.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. V. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. J. Heyd, E. N. Brothers, K. N. Kudin, V. N. Staroverov, T. A. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. P. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman, and D. J. Fox, Gaussian, Inc., Wallingford CT, 2016.
- [S6] F. Weigend, R. Ahlrichs, Phys. Chem. Chem. Phys. 2005, 7, 3297.
- [S7] Y. Zhao, D. G. Truhlar, Theor. Chem. Acc. 2008, 120, 215.
- [S8] A. V. Marenich, C. J. Cramer, D. G. Truhlar, J. Phys. Chem. B 2009, 113, 6378.
- [S9] Y. Zhao, D. G. Truhlar, J. Chem. Phys. 2006, 125, 194101.

[S10] a) H. Dunning Jr., P. J. Hay, in *Modern Theoretical Chemistry*, Ed. H. F. Schaefer III, Vol. 3 (Plenum, New York, 1977) 1–28; b) P. J. Hay, W. R. Wadt, *J. Chem. Phys.* 1985, 82, 270; c) W. R. Wadt, P. J. Hay, *J. Chem. Phys.* 1985, 82, 284; d) P. J. Hay, W. R. Wadt, *J. Chem. Phys.* 1985, 82, 299.

[S11] a) P. Pracht, F. Bohle, S. Grimme, *Phys. Chem. Chem. Phys.* **2020**, *22*, 7169; b) S. Grimme, *J. Chem. Theory Comput.* **2019**, *15*, 2847.


[S12] C. Bannwarth, E. Caldeweyher, S. Ehlert, A. Hansen, P. Pracht, J. Seibert, S. Spicher, S. Grimme, *WIREs Comput. Mol. Sci.* **2020**, e01493.

[S13] T. Lu, F. Chen, J. Comput. Chem. 2012, 33, 580.


[S14] W. Humphrey, A. Dalke, K. Schulten, J. Molec. Graphics 1996, 14, 33.

## 5. NMR Spectra


# <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of S1




# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of S1




# <sup>19</sup>F NMR (564.67 MHz, CDCl<sub>3</sub>) spectrum of S1




# <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 1e




# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 1e




# <sup>19</sup>F NMR (564.67 MHz, CDCl<sub>3</sub>) spectrum of 1e




### <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 3aa




# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 3aa




## <sup>19</sup>F NMR (564.67 MHz, CDCl<sub>3</sub>) spectrum of 3aa




### <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 3ab




# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 3ab




## <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 3ac




# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 3ac




# <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 3ad




# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 3ad




# <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 3ae




# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 3ae




# <sup>19</sup>F NMR (564.67 MHz, CDCl<sub>3</sub>) spectrum of 3ae




#### <sup>1</sup>H NMR (399.78 MHz, CDCl<sub>3</sub>) spectrum of 3af




# <sup>13</sup>C{<sup>1</sup>H} NMR (100.53 MHz, CDCl<sub>3</sub>) spectrum of 3af




# <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 3ag




# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 3ag




#### <sup>1</sup>H NMR (594.17 MHz, CDCl<sub>3</sub>) spectrum of 3ah




# <sup>13</sup>C{<sup>1</sup>H} NMR (149.41 MHz, CDCl<sub>3</sub>) spectrum of 3ah




# <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 3ai




# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 3ai




## <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 3aj




# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 3aj




#### <sup>1</sup>H NMR (599.67 MHz, CDCl<sub>3</sub>) spectrum of 3ak




# <sup>13</sup>C{<sup>1</sup>H} NMR (149.41 MHz, CDCl<sub>3</sub>) spectrum of 3ak




### <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 3al




# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 3al




#### <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 3bb




# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 3bb




# <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 3cb




# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 3cb




# <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 3db




# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 3db




# <sup>19</sup>F NMR (564.67 MHz, CDCl<sub>3</sub>) spectrum of 3db




#### <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 3eb




# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 3eb




### <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 3fb




# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 3fb




#### <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 3gb




# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 3gb




### <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 3hb



# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 3hb



#### <sup>1</sup>H NMR (600.17 MHz, CDCl<sub>3</sub>) spectrum of 3ib



# <sup>13</sup>C{<sup>1</sup>H} NMR (150.92 MHz, CDCl<sub>3</sub>) spectrum of 3ib

